A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4+ T-cell count was observed for 8 months. This case report shows the first lenacapavir experience in Asia in a heavily treatment-experienced HIV patient with limited treatment options.
Abstract
Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4+ T-cell count was observed for 8 months. This case report shows the first lenacapavir experience in Asia in a heavily treatment-experienced HIV patient with limited treatment options.
참고문헌 (10)
- Rhee SY, "HIV-1 transmitted drug resistance surveillance : shifting trends in study design and prevalence estimates", J Int AIDS Soc, 23, pp.e25611~ (2020)
- HIV drug resistance report 2019, "World Health Organization", World Health Organization, ~ (2019)
- Park M, "The trend of transmitted drug resistance in newly diagnosed antiretroviralnaive HIV", AIDS patients during 1999-2012 in South Korea, 2016, pp.81, 53~57
- Oh SM, "Resistance trends of antiretroviral agents in people with human immunodeficiency virus in Korea, 2012-2020", Infect Chemother, 55, pp.328~336 (2023)
- Choi JY, "The prevalence of antiretroviral multidrug resistance in highly active antiretroviral therapy-treated patients with HIV", AIDS between 2004and 2009 in South Korea, 2014, pp.60, 154~160
- Lee NE, "Lenacapavir and the novel HIV-1 capsid inhibitors : an emerging therapy in the management of multidrugresistant HIV-1 virus", Curr Opin Infect Dis, 36, pp.15~19 (2023)
- Segal-Maurer S, "Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection", N Engl J Med, 386, pp.1793~1803 (2022)
- Marcelin AG, "Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and-experienced patients", J Antimicrob Chemother, 75, pp.1588~1590 (2020)
- Yant SR, "In vitro resistance profile of GS-6207, a first-in-class picomolar HIV capsid inhibitor in clinical development as a novel longacting antiretroviral agent", Proceedings of the 10th IAS Conference on HIV Science (IAS 2019) (2019), International AIDS Society
- Link JO, "Clinical targeting of HIV capsid protein with a long-acting small molecule", Nature, 584, pp.614~618 (2020)